Efficacy of a ketogenic diet in resistant myoclono-astatic epilepsy: A French multicenter retrospective study
Related Experiment Video
Updated: Mar 6, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Elodie Stenger1, Mickael Schaeffer1, Claude Cances2
1Hôpital Universitaire de Strasbourg, Centre de Référence des Epilepsies Rares, France.
Insights
Early ketogenic diet (KD) for myoclono-astatic epilepsy (MAE) shows significant seizure reduction and remission. This treatment also leads to better cognitive outcomes in children with drug-resistant epilepsy.
Area of Science:
- Epilepsy research
- Pediatric neurology
- Ketogenic diet therapy
Background:
- Myoclono-astatic epilepsy (MAE) is a severe form of childhood epilepsy.
- Drug-resistant epilepsy often requires alternative treatment strategies.
- Ketogenic diet (KD) has shown promise in managing refractory epilepsy.
Purpose of the Study:
- To evaluate the efficacy of early ketogenic diet (KD) introduction in children with drug-resistant myoclono-astatic epilepsy (MAE).
- To assess the impact of KD on seizure control, epilepsy, and developmental outcomes.
- To determine if early KD intervention correlates with improved cognitive function.
Main Methods:
- A multicenter study included 50 children with severe MAE treated with KD.
- Seizure frequency and EEG were monitored before KD and at 2, 6 months, and during follow-up.
- Developmental outcomes were assessed during the last follow-up.
Main Results:
- After 6 months, 54% of patients achieved seizure freedom, and 86% had >70% seizure reduction within 2 months.
- Early KD treatment (after 4 AEDs failed) showed a clear benefit in 44% of patients.
- Earlier KD initiation (after 3 AEDs failed) correlated with better cognitive outcomes, and 50% of patients had normal development.
Conclusions:
- Early introduction of KD in resistant MAE provides a persistent anticonvulsant effect.
- KD treatment leads to long-term seizure remission and improved developmental outcomes.
- Timely KD intervention is crucial for enhancing cognitive function in pediatric epilepsy patients.
Objective:
Recent studies have suggested that the early introduction of a ketogenic diet (KD) could improve seizure control in myoclono-astatic epilepsy (MAE). This multicenter study sought to identify the benefits of KD use on seizure control and epilepsy and on developmental outcomes in children with resistant MAE.
Methods:
Fifty children who were diagnosed with severe MAE in the French network of Reference Centers for Rare Epilepsies and who were treated with KD between 2000 and 2013 were included in this study. The seizure frequency and EEG recordings were assessed two weeks before KD introduction, 2 and 6 months after, and during the last follow-up, which also included an assessment of developmental outcome.
Results:
Patients had a median follow up of 52 months (range 13-136) and received 4.3 antiepileptic drugs [2-9] before KD introduction. Fifty-four percent (54%) of our patients were seizure-free after 6 months of KD or more, and 86% experienced more than a 70% seizure reduction after 2 months of KD. Forty-four percent (44%) of them had a clear benefit of early KD treatment (after four AEDs failed). Early KD treatment did not result in a greater seizure reduction (p=0.055), but significantly resulted in remission (p<0.028). Fifty percent of patients with resistant MAE had normal development outcomes. Earlier KD treatment, after three AEDs failed, was correlated with a better cognitive outcome (p<0.01).
Significance:
Early introduction of KD treatment in resistant MAE has a strong, persistent anticonvulsant effect with long-term remission and better cognitive outcomes.
More Related Videos
08:47Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...